{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:09:38Z","timestamp":1793120978916,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University of Ghana\u2019s Office of Research Innovation and Development","award":["URGF\/14ECG-0052022-2023"],"award-info":[{"award-number":["URGF\/14ECG-0052022-2023"]}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center at the National Institutes of Health","doi-asserted-by":"crossref","award":["D43 TW010055"],"award-info":[{"award-number":["D43 TW010055"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH grant","award":["K24AI134359"],"award-info":[{"award-number":["K24AI134359"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00762-4","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T07:19:42Z","timestamp":1753514382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["HIV drug resistance in children and adolescents on NNRTI-based antiretroviral therapy and subsequent virologic response to dolutegravir-based regimens in Ghana"],"prefix":"10.1186","volume":"22","author":[{"given":"Adwoa K.A","family":"Afrane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Novitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Hague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwamena","family":"Sagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakubu","family":"Alhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelyn Assimeng","family":"Dame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Martyn-Dickens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lartey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamenla","family":"Goka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwasi","family":"Torpey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awewura","family":"Kwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"762_CR1","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","volume":"5","author":"RL Hamers","year":"2018","unstructured":"Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV. 2018;5:e588\u201396. https:\/\/doi.org\/10.1016\/S2352-3018(18)30173-5.","journal-title":"Lancet HIV"},{"key":"762_CR2","doi-asserted-by":"publisher","unstructured":"Ndashimye E, Arts EJ. The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030. Infect Dis Poverty. 2019;8. https:\/\/doi.org\/10.1186\/S40249-019-0573-1.","DOI":"10.1186\/S40249-019-0573-1"},{"key":"762_CR3","doi-asserted-by":"publisher","unstructured":"Schlatter AF, Deathe AR, Vreeman RC. The need for pediatric formulations to treat children with HIV. AIDS Res Treat 2016;2016. https:\/\/doi.org\/10.1155\/2016\/1654938","DOI":"10.1155\/2016\/1654938"},{"key":"762_CR4","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/JAC\/DKAD334","volume":"78","author":"ABD Djiyou","year":"2023","unstructured":"Djiyou ABD, Penda CI, Madec Y, Ngondi GD, Moukoko A, Eboumbou CE, et al. Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia. J Antimicrob Chemother. 2023;78:2938\u201342. https:\/\/doi.org\/10.1093\/JAC\/DKAD334.","journal-title":"J Antimicrob Chemother"},{"key":"762_CR5","doi-asserted-by":"publisher","unstructured":"Ciss\u00e9 AM, Laborde-Balen G, K\u00e9b\u00e9-Fall K, Dram\u00e9 A, Diop H, Diop K, et al. High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal. BMC Pediatr. 2019;19. https:\/\/doi.org\/10.1186\/S12887-019-1420-Z.","DOI":"10.1186\/S12887-019-1420-Z"},{"key":"762_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/QAI.0000000000002850","volume":"89","author":"W Nyandiko","year":"2022","unstructured":"Nyandiko W, Holland S, Vreeman R, DeLong AK, Manne A, Novitsky V, et al. HIV-1 treatment failure, drug resistance and clinical outcomes in Perinatally-Infected children and adolescents failing 1st-Line antiretroviral therapy in Western Kenya. J Acquir Immune Defic Syndr. 2022;89:231. https:\/\/doi.org\/10.1097\/QAI.0000000000002850.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"762_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/QAD.0000000000002470","volume":"34","author":"M Salou","year":"2020","unstructured":"Salou M, Butel C, Comlan AS, Konou AA, Tegueni K, Ehlan A, et al. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa. AIDS. 2020;34:783\u20137. https:\/\/doi.org\/10.1097\/QAD.0000000000002470.","journal-title":"AIDS"},{"key":"762_CR8","doi-asserted-by":"publisher","unstructured":"Afrane AKA, Goka BQ, Renner L, Yawson AE, Alhassan Y, Owiafe SN, et al. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern ghana: a cross-sectional study. BMC Infect Dis. 2021;21. https:\/\/doi.org\/10.1186\/S12879-021-06459-Z.","DOI":"10.1186\/S12879-021-06459-Z"},{"key":"762_CR9","unstructured":"HIV Drug Resistance Database. n.d. https:\/\/hivdb.stanford.edu\/ (accessed April 1, 2025)."},{"key":"762_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/JPIDS\/PIAD040","volume":"12","author":"SA Khamadi","year":"2023","unstructured":"Khamadi SA, Bahemana E, Dear N, Mavere C, George F, Kapene R, et al. Factors associated with viral suppression and drug resistance in children and adolescents living with HIV in care and treatment programs Iestabn Southern Tanzania. J Pediatr Infect Dis Soc. 2023;12:353. https:\/\/doi.org\/10.1093\/JPIDS\/PIAD040.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"762_CR11","doi-asserted-by":"publisher","first-page":"e0187566","DOI":"10.1371\/journal.pone.0187566","volume":"12","author":"J Fokam","year":"2017","unstructured":"Fokam J, Billong SC, Jogue F, Moyo Tetang Ndiang S, Nga Motaze AC, Paul KN, et al. Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaound\u00e9-Cameroon. PLoS ONE. 2017;12:e0187566. https:\/\/doi.org\/10.1371\/journal.pone.0187566.","journal-title":"PLoS ONE"},{"key":"762_CR12","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/JAC\/DKU104","volume":"69","author":"PR S\u00e1nchez","year":"2014","unstructured":"S\u00e1nchez PR, Holgu\u00edn A. Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. J Antimicrob Chemother. 2014;69:2032\u201342. https:\/\/doi.org\/10.1093\/JAC\/DKU104.","journal-title":"J Antimicrob Chemother"},{"key":"762_CR13","unstructured":"Consolidated. accessed April 4, guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240031593 (2025)."},{"key":"762_CR14","unstructured":"Consolidated guidelines for HIV care in Ghana| GPC. 2022. https:\/\/hivpreventioncoalition.unaids.org\/en\/resources\/consolidated-guidelines-hiv-care-ghana-0 (accessed April 4, 2025)."},{"key":"762_CR15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMOA2108793\/","volume":"385","author":"A Turkova","year":"2021","unstructured":"Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, et al. Dolutegravir as First- or Second-Line treatment for HIV-1 infection in children. N Engl J Med. 2021;385:2531\u201343. https:\/\/doi.org\/10.1056\/NEJMOA2108793\/SUPPL_FILE\/NEJMOA2108793_DATA-SHARING.PDF.","journal-title":"N Engl J Med"},{"key":"762_CR16","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/S2352-3018(24)00155-3","volume":"12","author":"E White","year":"2025","unstructured":"White E, Kityo C, Spyer MJ, Mujuru HA, Nankya I, Kekitiinwa AR, et al. Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025;12:e201\u201313. https:\/\/doi.org\/10.1016\/S2352-3018(24)00155-3.","journal-title":"Lancet HIV"},{"key":"762_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/JPIDS\/PIY139","volume":"9","author":"RM Viani","year":"2020","unstructured":"Viani RM, Ruel T, Alvero C, Fenton T, Acosta EP, Hazra R, et al. Long-Term safety and efficacy of dolutegravir in Treatment-Experienced adolescents with human immunodeficiency virus infection: results of the IMPAACT P1093 study. J Pediatr Infect Dis Soc. 2020;9:159\u201365. https:\/\/doi.org\/10.1093\/JPIDS\/PIY139.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"762_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/S11904-009-0026-8","volume":"6","author":"J Haberer","year":"2009","unstructured":"Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. Curr HIV\/AIDS Rep. 2009;6:194\u2013200. https:\/\/doi.org\/10.1007\/S11904-009-0026-8.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"762_CR19","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/S2352-3018(22)00327-7","volume":"10","author":"R Kantor","year":"2023","unstructured":"Kantor R, Gupta RK. We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy. Lancet HIV. 2023;10:e202\u20138. https:\/\/doi.org\/10.1016\/S2352-3018(22)00327-7.","journal-title":"Lancet HIV"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00762-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00762-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00762-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T07:19:44Z","timestamp":1753514384000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00762-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00762-4","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Korle Bu Teaching Hospital ((KBTH-IRB\/ 00060\/2017) for studies involving humans. Written informed consent, including consent to store and use samples for HIVDR testing, was obtained from the parents or legal guardians of each minor participant before enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"74"}}